Fulcrum Therapeutics, Inc.
No enriched coverage for $FULC in the last 7 days.
TANG KEVIN purchased 167,616 indirectly-held shares of Fulcrum Therapeutics, Inc. (FULC) at an average of $3.55 ($3.52–$3.56, $0.59M total) across 2 trades over 2026-07-16 to 2026-07-17.
TANG KEVIN purchased 249,946 indirectly-held shares of Fulcrum Therapeutics, Inc. (FULC) at an average of $3.56 ($3.54–$3.58, $0.89M total) across 4 trades over 2026-07-13 to 2026-07-15.
Fulcrum Therapeutics, Inc. (FULC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001680581 0001680581 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24,
Recent FULC coverage spans financial news, insider activity and corporate actions.
In the last 30 days, FULC insiders filed 6 SEC Form 4 transactions — 6 purchases ($1.5M) and no sales. The most active reporter was TANG KEVIN with 6 filings.
The filing is a new, company-specific insider buying datapoint, but it is indirect and lacks a 10b5-1 plan, limiting signal strength.
The filing signals insider accumulation, but it is not a fundamental catalyst like earnings, guidance, or a deal.
Routine shareholder voting outcomes; no new operating, financial, or regulatory catalyst beyond governance housekeeping.
Retention/Change-in-Control benefit amendments follow a restructuring tied to a discontinued program, signaling ongoing corporate actions and potential M&A optionality.
Sell-side downgrade and lower target likely pressure near-term sentiment and can widen downside risk for FULC holders.
alphai scores every news story that mentions FULC with an AI model for sentiment and relevance, and aggregates insider trades from Fulcrum Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TANG KEVIN purchased 167,616 indirectly-held shares of Fulcrum Therapeutics, Inc. (FULC) at an average of $3.55 ($3.52–$3.56, $0.59M total) across 2 trades over 2026-07-16 to 2026-07-17.
2 min readTANG KEVIN purchased 249,946 indirectly-held shares of Fulcrum Therapeutics, Inc. (FULC) at an average of $3.56 ($3.54–$3.58, $0.89M total) across 4 trades over 2026-07-13 to 2026-07-15.
2 min readFulcrum Therapeutics, Inc. (FULC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001680581 0001680581 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24,
2 min readFulcrum Therapeutics, Inc. (FULC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001680581 0001680581 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05,
3 min readLeerink Partners downgraded Fulcrum Therapeutics (NASDAQ:FULC) from “outperform” to “market perform,” setting a $4.00 price objective, implying 37.69% downside from the current price, according to MarketBeat. Other firms also cut ratings and targets to $3.00–$4.00. The stock opened at $6.42; it reported EPS of -$0.25 for the April 27 quarter.
4 min readFulcrum Therapeutics (NASDAQ:FULC) shares fell 49.69% to $3.23 in after-hours after the company said it is discontinuing pociredir for sickle cell disease, citing FDA concerns about the benefit-risk profile linked to malignancy risks seen with Tazverik. Fulcrum also launched a strategic alternatives review and plans to cut expenses. It reported $333.3 million in cash as of March 31, 2026.
6 min readFulcrum Therapeutics will host a conference call and webcast on February 24, 2026, to present 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial of pociredir for sickle cell disease. Pociredir is an investigational oral small-molecule inhibitor designed to increase fetal hemoglobin, which has shown dose-dependent increases in HbF and improvements in markers of hemolysis and anemia, with general tolerability across dose cohorts. Dr. Martin Steinberg, a leading hematologist specializing in sickle cell disease, will join Fulcrum management for the presentation.
4 min readFulcrum Therapeutics, Inc. announced it granted non-statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan. This comes as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options allow the purchase of 30,400 shares at an exercise price of $10.84 per share, vesting over four years.
2 min readFulcrum Therapeutics (FULC) is launching a $150 million public stock offering to raise capital, enlisting several financial institutions to manage the sale. The biotechnology company focuses on treatments for muscular dystrophy and hemoglobinopathies, demonstrating strong balance sheet health despite challenges in profitability. The offering aims to support its clinical development programs.
3 min readU.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday. Shares of Helmerich and Payne Inc ( NYSE:HP ) fell sharply in pre-market trading after the company reported fourth-quarter financial results.
5 min read
